You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金|中金:上調康方生物目標價至90港元 旗下伊喜寧新藥上市許可申請獲批
格隆匯 10-14 15:33
康方生物早前公佈,旗下伊喜寧(伊努西單抗,PCSK9)新藥上市許可申請,已獲中國國家藥品監督管理局批准,為公司在非腫瘤領域首個獲批產品,亦是公司第五個進入商業化階段的自主創新藥物。中金髮表研究報吿引述2020年一份研究報吿指,中國內地18歲以上人口高血脂症整體盛行率為35.6%,他汀類藥物仍然是當地治療高血脂症的主要藥物,至於PCSK9抑制劑已於臨牀試驗及商業化中證明其市場潛力。中金表示,維持對康方生物2024及2025財年盈利預測不變。鑑於公司各類產品的進展及H股流動性的改善,該行將其目標價上調28.6%至90港元,維持“跑贏大市”評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account